Results 11 to 20 of about 3,281 (174)
A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies [PDF]
Haematologica, 2020 Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy delays, dose reductions, and discontinuation. There is no FDA-approved agent available to manage CIT.
Hanny Al-Samkari +5 more
doaj +2 more sources
Uso de romiplostim en trombocitopenia inmunitaria: experiencia en Cuenca (Ecuador) [PDF]
Biomédica: revista del Instituto Nacional de SaludIntroducción. El consenso internacional y la guía del 2019 de la American Society of Hematology, establecieron a los análogos de la trombopoyetina como medicamentos de segunda línea para tratar la trombocitopenia inmunitaria primaria.
Héctor Chiang-Wong +1 more
doaj +2 more sources
Human Pathology Reports, 2023 We report a patient with chronic immune thrombocytopenia purpura who underwent bone marrow biopsies before and after treatment with romiplostim. The biopsy after treatment with romiplostim showed a marked increase in the numbers of megakaryocytes which ...
Charles M. Lombard +2 more
doaj +2 more sources
Romiplostim in chemotherapy‐induced thrombocytopenia: A review of the literature
Cancer MedicineChemotherapy‐induced thrombocytopenia (CIT) is a common challenge of cancer therapy and can lead to chemotherapy dose reduction, delay, and/or discontinuation, affecting relative dose intensity, and possibly adversely impacting cancer care.
Gerald A. Soff +4 more
doaj +2 more sources
Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series
Hematology/Oncology and Stem Cell Therapy, 2020 Thrombocytopenia is a relatively common complication following allogeneic hematopoietic stem cell transplantation and is associated with increased bleeding, transfusion requirements, chronic graft-versus-host disease, and all-cause mortality.
Guido Lancman +2 more
doaj +2 more sources
Journal of Veterinary Internal MedicineBackground Romiplostim, a thrombopoietin analog, is commonly used to treat immune‐mediated thrombocytopenia (ITP) in humans, but its use in dogs remains limited.
Min‐Ok Ryu +5 more
doaj +2 more sources
Case Reports in Hematology, 2018 Romiplostim is a peptibody, which stimulates platelet production by a mechanism similar to that of endogenous thrombopoietin. It has an established indication as second-line therapy in patients with chronic immune thrombocytopenia (ITP).
Jasjit Kaur Rooprai, Karima Khamisa
doaj +2 more sources
Hematology, 2023 Thrombocytopenia is a common and serious complication that can occur following hematopoietic stem cell transplantation (HSCT), and it contributes to increased morbidity and mortality.
Abdulrahman F. Al-Mashdali +3 more
doaj +2 more sources
Total remission of severe immune thrombocytopenia after short term treatment with romiplostim
Hematology Reports, 2011 Immune thrombocytopenia (ITP) in adults is an acquired chronic immune-mediated disorder defined by isolated thrombocytopenia. In recent years, an improved understanding of the pathophysiology of ITP has been achieved and is now accepted that the disorder
Efthymia Vlachaki +6 more
doaj +2 more sources
Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia
Journal of Blood Medicine, 2016 Prakash Vishnu,1 David M Aboulafia1,2 1Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, 2Division of Hematology, University of Washington, Seattle, WA, USA Abstract: Inhibition of platelet production and mediated by ...
Vishnu P, Aboulafia DM
doaj +1 more source